• Sinovac Biotech received a Nasdaq delisting determination dated May 22, 2026, citing a late Form 20-F annual report for 2025.
• Nasdaq warned the shares face suspension and delisting unless a panel hearing was requested by May 29, 2026.
• A hearing request was filed, triggering an automatic 22-day stay from the Staff Determination date; a longer stay was also sought.
• The late filing follows a May 20, 2026 notice that the company had regained compliance as of May 8, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinovac Biotech Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260529895816) on May 29, 2026, and is solely responsible for the information contained therein.